Hormone Replacement Therapy and Colorectal Adenoma Recurrence Among Women in the Polyp Prevention Trial

• Published in: JNCI : Journal of the National Cancer Institute 2001-12, Vol.93 (23), p.1799-1805
• Main Authors: Woodson, Karen, Lanza, Elaine, Tangrea, Joseph A., Albert, Paul S., Slattery, Martha, Pinsky, Joan, Caan, Bette, Paskett, Electra, Iber, Frank, Kikendall, J. Walter, Lance, Peter, Shike, Moshe, Weissfeld, Joel, Schatzkin, Arthur
• Format: Article
• Language: English
• Subjects: Adenoma - drug therapy; Adenoma - pathology; Adenoma - prevention & control; Adult; Age Factors; Aged; Biological and medical sciences; Colonoscopy; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - pathology; Colorectal Neoplasms - prevention & control; Estrogens - therapeutic use; Female; Gastroenterology. Liver. Pancreas. Abdomen; Hormone Replacement Therapy; Humans; Medical sciences; Menopause; Middle Aged; Odds Ratio; Postmenopause; Progestins - therapeutic use; Recurrence; Regression Analysis; Risk Factors; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Time Factors; Tumors
• ISSN: 0027-8874; 1460-2105
• DOI: 10.1093/jnci/93.23.1799

Background: Epidemiologic studies have suggested that estrogen may protect against the development of colorectal cancers and adenomatous polyps. We conducted a prospective study to evaluate the association between hormone replacement therapy (HRT) and adenoma recurrence among perimenopausal and postmenopausal women participating in the Polyp Prevention Trial, a randomized dietary intervention study of individuals with colorectal adenomas. Methods: We used a questionnaire and interviews to collect detailed information, at baseline and at each of four annual study visits, from 620 women regarding hormone use, menopausal status, diet, alcohol consumption, and other risk factors. Adenoma recurrence was ascertained by complete colonoscopy at baseline and after 1 and 4 years. Logistic regression models were used to evaluate the association between hormone use and adenoma recurrence after adjusting for intervention group and for age and body mass index at baseline. All statistical tests were two-sided. Results: Adenomas recurred in 200 women. There was no overall association between adenoma recurrence and either overall hormone use (odds ratio [OR] = 1.01; 95% confidence interval [CI] = 0.70 to 1.45), combined estrogen and progestin use (OR = 0.94; 95% CI = 0.57 to 1.56), or unopposed estrogen use (OR = 1.04; 95% CI = 0.68 to 1.59). HRT use was associated with a reduction in risk for recurrence of distal adenomas (OR = 0.56; 95% CI = 0.32 to 1.00) and a statistically nonsignificant increase in risk for recurrence of proximal adenomas (OR = 1.39; 95% CI = 0.85 to 2.26). We observed a statistically significant interaction between the HRT–adenoma recurrence association and age (P = .02). HRT was associated with a 40% reduced risk of adenoma recurrence among women older than 62 years (OR = 0.58; 95% CI = 0.35 to 0.97) but with an increased risk among women younger than 62 years (OR = 1.99; 95% CI = 1.11 to 3.55). Conclusions: HRT was not associated with a reduced risk for overall adenoma recurrence in this trial cohort, although there was a suggestion of an age interaction. The effect of age on the association needs to be confirmed in other adenoma recurrence trials.